DFFVX
Price
$34.13
Change
-$1.40 (-3.94%)
Updated
Dec 18 closing price
ROFRX
Price
$13.28
Change
-$0.52 (-3.77%)
Updated
Dec 18 closing price
Ad is loading...

DFFVX vs ROFRX

Header iconDFFVX vs ROFRX Comparison
Open Charts DFFVX vs ROFRXBanner chart's image
DFA US Targeted Value I
Price$34.13
Change-$1.40 (-3.94%)
VolumeN/A
CapitalizationN/A
Royce Small-Cap Opportunity R
Price$13.28
Change-$0.52 (-3.77%)
VolumeN/A
CapitalizationN/A
DFFVX vs ROFRX Comparison Chart
Loading...
View a ticker or compare two or three
VS
DFFVX vs. ROFRX commentary
Dec 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DFFVX is a Hold and ROFRX is a Hold.

FUNDAMENTALS
Fundamentals
DFFVX has more cash in the bank: 14B vs. ROFRX (1.22B). DFFVX pays higher dividends than ROFRX: DFFVX (1.37) vs ROFRX (0.00). DFFVX was incepted earlier than ROFRX: DFFVX (25 years) vs ROFRX (18 years). ROFRX is a more actively managed with annual turnover of: 35.00 vs. DFFVX (20.00). DFFVX has a lower initial minimum investment than ROFRX: DFFVX (0) vs ROFRX (1000). DFFVX annual gain was more profitable for investors over the last year : 15.38 vs. ROFRX (7.73). DFFVX return over 5 years is better than : 60.26 vs. ROFRX (24.21).
DFFVXROFRXDFFVX / ROFRX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence25 years18 years-
Gain YTD13.0334.704277%
Front LoadN/AN/A-
Min. Initial Investment01000-
Min. Initial Investment IRAN/AN/A-
Net Assets14B1.22B1,152%
Annual Yield % from dividends1.370.00-
Returns for 1 year15.387.73199%
Returns for 3 years26.84-2.27-1,184%
Returns for 5 years60.2624.21249%
Returns for 10 years71.1111.74606%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
VXRT0.590.01
+0.99%
Vaxart
DVA147.57-3.02
-2.01%
DaVita
PINC21.17-0.59
-2.71%
Premier
LXU8.25-0.41
-4.73%
LSB Industries
SYRS0.21-0.01
-4.91%
Syros Pharmaceuticals